CyDex Pharmaceuticals Presents Phase 2 Clinical Trial Results for Captisol-Enabled(R) Budesonide/Azelastine Combination Solution Nasal Spray at American Academy of Allergy, Asthma and Immunology (AAAAI) Meeting

Published: Mar 16, 2009

LENEXA, Kan.--(BUSINESS WIRE)--CyDex Pharmaceuticals, Inc. today announced the presentation of Phase 2 clinical trial results of its novel, proprietary Captisol-Enabled® budesonide/azelastine nasal spray (CDX-313) for seasonal allergic rhinitis (SAR). The budesonide/azelastine combination nasal spray demonstrated statistically significant improved results over a nasal spray placebo.

Back to news